Disseminated gonococcal infection in a patient with paroxysmal nocturnal hemoglobinuria having received ravulizumab and meningococcal vaccine

Disseminated gonococcal infection in a patient with paroxysmal nocturnal hemoglobinuria having received ravulizumab and meningococcal vaccine

Bibliographic Details
Main Authors:	Zhi-Ye Yu, Ming-Jui Tsai, Yu-Jen Lin, Wang-Da Liu, Sheng-Chieh Chou, Chien-Ching Hung
Format:	Article
Language:	English
Published:	Elsevier 2020-08-01
Series:	Journal of Microbiology, Immunology and Infection
Subjects:	Humanized monoclonal antibody Complement component 5 (C5) inhibitor Innate immunity Gonorrhea Sexually transmitted infection
Online Access:	http://www.sciencedirect.com/science/article/pii/S1684118220301547

Similar Items

Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
by: Gurnari C, et al.
Published: (2021-12-01)

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
by: Sufana Shikdar, et al.
Published: (2021-10-01)

Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria
by: Anna Gaya, et al.
Published: (2023-08-01)

Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
by: Nicole Galli, et al.
Published: (2023-10-01)

Recent Progress Towards a Gonococcal Vaccine
by: Stavros A. Maurakis, et al.
Published: (2022-04-01)

No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab.
by: Ferras Alashkar, et al.
Published: (2020-01-01)

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
by: Robert M. Stern, et al.
Published: (2019-09-01)

Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
by: Carolyn E. Schwartz, et al.
Published: (2021-09-01)

Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations
by: Oliver M, et al.
Published: (2023-12-01)

Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
by: Wolfgang Füreder, et al.
Published: (2020-08-01)

Gonococcal epididymo-orchitis in an octogenarian
by: Ali Ahmad, et al.
Published: (2020-07-01)

Disseminated Gonococcal Infection Associated with Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria: A Case Report and Literature Review
by: Saito M, et al.
Published: (2020-07-01)

Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
by: Vu T, et al.
Published: (2023-12-01)

Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties
by: Bruno Fattizzo, et al.
Published: (2021-03-01)

Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist’s Opinion
by: Guido Gembillo, et al.
Published: (2020-04-01)

National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria
by: A. D. Kulagin, et al.
Published: (2014-09-01)

National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria
by: A. D. Kulagin, et al.
Published: (2014-09-01)

Gonococcal conjunctivitis after incomplete treatment of gonococcal urethritis
by: Wang MF, et al.
Published: (2019-05-01)

Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation
by: Brodsky Andrés, et al.
Published: (2012-09-01)

Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network
by: Jesse Fishman, et al.
Published: (2023-04-01)

Hemolytic reaction in the washed salvaged blood of a patient with paroxysmal nocturnal hemoglobinuria
by: Yuko Kawamoto, et al.
Published: (2019-05-01)

Paroxysmal nocturnal hemoglobinuria in a patient post COVID‐19 virus infection: A case report with literature review
by: Mohammed Albalawi, et al.
Published: (2023-10-01)

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria
by: David Dingli, et al.
Published: (2024-12-01)

Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria
by: Hakan Göker, et al.
Published: (2011-08-01)

Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria
by: Hakan Göker, et al.
Published: (2011-09-01)

Treatment of paroxysmal nocturnal hemoglobinuria
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Treatment of paroxysmal nocturnal hemoglobinuria
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Paroxysmal nocturnal hemoglobinuria pnh
by: Hanan Hamed
Published: (2020-10-01)

Paroxysmal Nocturnal Hemoglobinuria Superimposed with Preeclampsia
by: Mann-Ling Chen, et al.
Published: (2006-09-01)

Risk Factors for Patients with Gonococcal Urethritis at Dr. Hasan Sadikin General Hospital Bandung, Indonesia in 2013–2019
by: Pati Aji Achdiat, et al.
Published: (2023-03-01)

Rare presentation of vertebral discitis, osteomyelitis and polyarticular septic arthritis due to disseminated Neisseria gonorrhea infection
by: Moni Roy, et al.
Published: (2020-01-01)

Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population
by: Cheng WY, et al.
Published: (2022-05-01)

P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS
by: A. Kulasekararaj, et al.
Published: (2022-06-01)

P834: REAL-WORLD EVIDENCE OF SAFETY AND EFFECTIVENESS OF ECULIZUMAB AND SWITCH TO RAVULIZUMAB IN A SWISS PATIENT POPULATION WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: A. Rovó, et al.
Published: (2022-06-01)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
by: John Devin Peipert, et al.
Published: (2020-01-01)

Commensal <i>Neisseria</i> Are Shared between Sexual Partners: Implications for Gonococcal and Meningococcal Antimicrobial Resistance
by: Christophe Van Dijck, et al.
Published: (2020-03-01)

Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature
by: Juri Alessandro Giannotta, et al.
Published: (2021-11-01)

Association Between Gonococcal Infection and a Common Genetic Deletion in Sperm Mitochondrial
by: Mohanad Jawad Kadhim, et al.
Published: (2023-06-01)

Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
by: Carlos Bravo-Perez, et al.
Published: (2023-09-01)

Paroxysmal nocturnal hemoglobinuria: the path to diagnosis
by: E. F. Makhnyr, et al.
Published: (2019-04-01)